Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.68 |
| ▸ | STS | P08842 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203242 | 0.89 | HTR6 (0.52) | HTR6GPR119PIK3CA | |
| SCHEMBL6588061 | 0.81 | HTR6 (0.68) | HTR6STSGPR119MAPTPIK3CA | |
| SCHEMBL5201051 | 0.81 | HTR6 (1.00) | HTR6THRBRXFP1 | |
| Hydrochloric Acid SCHEMBL6588564 | 0.81 | HTR6 (0.98) | HTR6THRBRXFP1 | |
| SCHEMBL28920485 | 0.80 | GPR119 (0.51) | HTR6STSTHRBRXFP1GPR119 | |
| SCHEMBL6586841 | 0.80 | HTR6 (0.42) | HTR6STSRXFP1CPT2CPT1A | |
| SCHEMBL27507704 | 0.78 | HTR6 (0.57) | HTR6THRB | |
| SCHEMBL6375028 | 0.77 | HTR6 (0.70) | HTR6STS | |
| SCHEMBL28920366 | 0.76 | TP53 (0.52) | STSRXFP1MAPT | |
| SCHEMBL6374896 | 0.76 | HTR6 (0.52) | HTR6STSGPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | SMITHKLINE BEECHAM PLC (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1414442-A1 | 3-ARYLSULFONYL-7-PIPERAZINYL- INDOLES, -BENZOFURANS AND -BENZOTHIOPHENES WITH 5-HT6 RECEPTOR AFFINITY FOR TREATING CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003013510-A1 | 3-ARYLSULFONYL-7-PIPERAZINYL- INDOLES, -BENZOFURANS AND -BENZOTHIOPHENES WITH 5-HT6 RECEPTOR AFFINITY FOR TREATING CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242589-A1 | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | HTR6, HTR7, HTR1A | HTR6 1/4885STS 1076/4885THRB 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.